Other research analysts have also issued reports about the stock. ValuEngine raised shares of BioTelemetry from a hold rating to a buy rating in a research note on Wednesday, October 2nd. Lake Street Capital reissued a buy rating and issued a $80.00 price objective (down from $90.00) on shares of BioTelemetry in a research report on Wednesday, November 6th. Finally, TheStreet raised BioTelemetry from a c+ rating to a b- rating in a research note on Wednesday, November 20th. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. BioTelemetry presently has a consensus rating of Buy and an average price target of $71.83.
Shares of BioTelemetry stock opened at $46.59 on Wednesday. The company has a quick ratio of 2.35, a current ratio of 2.46 and a debt-to-equity ratio of 0.51. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of 23.25, a PEG ratio of 2.41 and a beta of 1.32. BioTelemetry has a twelve month low of $37.07 and a twelve month high of $80.92. The business has a 50-day moving average price of $45.51 and a 200-day moving average price of $43.95.
BioTelemetry (NASDAQ:BEAT) last released its quarterly earnings data on Tuesday, November 5th. The medical research company reported $0.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.50 by $0.02. BioTelemetry had a net margin of 8.98% and a return on equity of 21.77%. The business had revenue of $111.30 million during the quarter, compared to analyst estimates of $111.19 million. During the same quarter last year, the business earned $0.53 earnings per share. BioTelemetry’s quarterly revenue was up 11.3% compared to the same quarter last year. On average, equities analysts expect that BioTelemetry will post 1.96 EPS for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the company. Amundi Pioneer Asset Management Inc. increased its holdings in BioTelemetry by 34.4% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 45,700 shares of the medical research company’s stock valued at $2,862,000 after buying an additional 11,700 shares during the period. Los Angeles Capital Management & Equity Research Inc. boosted its position in BioTelemetry by 71.9% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 7,553 shares of the medical research company’s stock valued at $364,000 after acquiring an additional 3,160 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of BioTelemetry by 73.8% in the 2nd quarter. Janus Henderson Group PLC now owns 16,137 shares of the medical research company’s stock valued at $777,000 after acquiring an additional 6,853 shares during the period. Envestnet Asset Management Inc. increased its holdings in shares of BioTelemetry by 38.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 31,469 shares of the medical research company’s stock valued at $1,515,000 after acquiring an additional 8,725 shares during the period. Finally, Swiss National Bank raised its position in shares of BioTelemetry by 3.0% in the 2nd quarter. Swiss National Bank now owns 62,500 shares of the medical research company’s stock worth $3,009,000 after acquiring an additional 1,800 shares in the last quarter. 93.75% of the stock is owned by hedge funds and other institutional investors.
BioTelemetry Company Profile
BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core lab services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in Healthcare, Research, and Corporate and Other segments.
Recommended Story: What are no-load funds?
Receive News & Ratings for BioTelemetry Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioTelemetry and related companies with MarketBeat.com’s FREE daily email newsletter.